Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kura Oncology Inc KURA

Healthcare Biotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that... see more

Recent & Breaking News (NDAQ:KURA)

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

GlobeNewswire December 8, 2023

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

GlobeNewswire November 28, 2023

Kura Oncology Reports Third Quarter 2023 Financial Results

GlobeNewswire November 2, 2023

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

GlobeNewswire November 2, 2023

Kura Oncology to Participate in Three Upcoming Investor Conferences

GlobeNewswire October 30, 2023

Kura Oncology to Report Third Quarter 2023 Financial Results

GlobeNewswire October 26, 2023

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

GlobeNewswire October 19, 2023

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

GlobeNewswire October 17, 2023

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 4, 2023

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

GlobeNewswire September 28, 2023

Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

GlobeNewswire September 19, 2023

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

GlobeNewswire August 14, 2023

Kura Oncology Reports Second Quarter 2023 Financial Results

GlobeNewswire August 3, 2023

Kura Oncology to Report Second Quarter 2023 Financial Results

GlobeNewswire July 27, 2023

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire June 14, 2023

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire June 13, 2023

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

GlobeNewswire June 11, 2023

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

GlobeNewswire May 30, 2023

Kura Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire May 23, 2023

Kura Oncology Reports First Quarter 2023 Financial Results

GlobeNewswire May 10, 2023